Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.

@article{Ye2011IndomethacinAS,
  title={Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression.},
  author={Cai-Guo Ye and William Ka-Kei Wu and John Hok-keung Yeung and Haitao Li and Zhi-jie Li and Clover Ching-Man Wong and Shun-xiang Ren and Lin Zhang and Kwok-pui Fung and Chi-hin Cho},
  journal={Cancer letters},
  year={2011},
  volume={304 2},
  pages={90-6}
}
Doxorubicin is a chemotherapeutic drug widely used for the treatment of hepatocellular carcinoma but its efficacy is restricted by multidrug resistance. Non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2-selective inhibitors exhibit anti-cancer properties as well as abilities to overcome drug resistance. In the present study, indomethacin (a NSAID) and SC236 (a COX-2-selective inhibitor) enhanced the cytotoxicity of doxorubicin in the hepatocellular carcinoma cell line… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Similar Papers

Loading similar papers…